GSK is smart. They will buy out a promising company like CUR for what will turnout to be a very cheap cost and as a result have therapies for Als, dementia, depression, spinal cord injury and stroke. Cur is the most inexpensive route to participate in what portends to be an major change in the approach to medicine ... cure it rather than mitigate the symptoms. China is already on board big time. Hopefully GSK knows the future is in regenerative medicine and not mitigation of symptoms. We shall see.
GSK sees the writing on the wall and is going to go big on consumer otc drugs and other consumables. Not everyone can afford a $1,000 pill. Insurance companies will go broke paying companies like GILD. Good move to roll out of GILD and into GSK before the entire world's health care system goes broke.